Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337966 | 1.00 | FOLH1 (0.55) | FOLH1TDP1ATMNPSR1POLB | |
| SCHEMBL30185966 | 0.92 | FOLH1 (0.47) | FOLH1TDP1ATMNPSR1POLB | |
| SCHEMBL29679271 | 0.91 | FOLH1 (0.47) | FOLH1TDP1ATMNPSR1POLB | |
| SCHEMBL17701139 | 0.90 | TDP1 (0.54) | TDP1ATMNPSR1POLBMEN1 | |
| SCHEMBL22518777 | 0.90 | TDP1 (0.54) | TDP1ATMNPSR1POLBMEN1 | |
| SCHEMBL23786252 | 0.88 | TDP1 (0.43) | FOLH1TDP1ATMNPSR1POLB | |
| SCHEMBL25963705 | 0.88 | TDP1 (0.43) | FOLH1TDP1ATMNPSR1POLB | |
| SCHEMBL20341538 | 0.87 | TDP1 (0.43) | FOLH1TDP1ATMNPSR1POLB | |
| SCHEMBL22736959 | 0.87 | TDP1 (0.43) | FOLH1TDP1ATMNPSR1POLB | |
| SCHEMBL20341481 | 0.87 | TDP1 (0.43) | FOLH1TDP1ATMNPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | RIGSHOSPITALET (DK) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | KLK3, FOLH1, PSMA7 | FOLH1 2/4885TDP1 3735/4885ATM 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.